Phaseline

Companies › PharmAbcine

PharmAbcine: clinical trials, targets and expected readouts

1 active drug program in 1 registered trial: 1 Phase 1; Oncology; next expected readout Oct 2029.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
PMC-309
monoclonal antibody against VISTA ligand
VSIRPhase 1Advanced or Metastatic Solid TumorsOct 2029

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT05957081PMC-309Phase 1Advanced or Metastatic Solid TumorsOncologyOct 2029

Targets

VSIR (1)

Companies with the same targets

–

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.